Therapeutic Update RE: Operationalizing Remdesivir

Posted on: April 12, 2022

The BC CTC and CTRAWG recommend that remdesivir be used as the first-line alternative IV treatment if nirmatrelvir-ritonavir (PAXLOVID) cannot be prescribed.

Click here for an updated Clinical Practice Guide for the Use of Therapeutics in Mild-Moderate COVID-19.

Practice Tool #1 – Assessment Guide for Clinicians.

Practice Tool #2 – Definitions of CEV/ Immunosuppressed.

 

IH

Therapeutic Update RE: Operationalizing Remdesivir

Information is considered to be true and correct at the date of publication, changes in circumstances after the time of publication may impact on the accuracy of the information.